Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study

PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies. PATIENTS AND METHODS: Lapatinib was admin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fouladi, Maryam, Stewart, Clinton. F., Blaney, Susan M., Onar-Thomas, Arzu, Schaiquevich, Paula, Packer, Roger J., Gajjar, Amar, Kun, Larry E., Boyett, James M., Gilbertson, Richard J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2953974/
https://ncbi.nlm.nih.gov/pubmed/20713864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.4687
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados